TG Therapeutics (NASDAQ:TGTX) PT Raised to $40.00

TG Therapeutics (NASDAQ:TGTX) had its price target hoisted by LADENBURG THALM/SH SH from $39.00 to $40.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. LADENBURG THALM/SH SH’s price target indicates a potential upside of 151.89% from the stock’s current price.

Other analysts have also issued research reports about the company. StockNews.com lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $25.00 price target on shares of TG Therapeutics in a research report on Thursday, April 18th. B. Riley increased their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. The Goldman Sachs Group increased their price target on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.17.

TG Therapeutics Trading Up 16.3 %

TGTX stock opened at $15.88 on Thursday. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of 794.40 and a beta of 2.33. The business has a 50 day simple moving average of $15.07 and a two-hundred day simple moving average of $14.32.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The business had revenue of $43.97 million for the quarter, compared to analysts’ expectations of $40.06 million. During the same period in the prior year, the firm earned ($0.39) EPS. Research analysts anticipate that TG Therapeutics will post -0.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently added to or reduced their stakes in TGTX. Pingora Partners LLC purchased a new position in shares of TG Therapeutics in the fourth quarter worth about $27,000. PNC Financial Services Group Inc. raised its stake in shares of TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares during the last quarter. Anchor Investment Management LLC purchased a new position in shares of TG Therapeutics in the fourth quarter worth about $80,000. NBC Securities Inc. purchased a new position in shares of TG Therapeutics in the third quarter worth about $58,000. Finally, REDW Wealth LLC purchased a new position in shares of TG Therapeutics in the third quarter worth about $84,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.